HTDS - Hard To Treat Diseases Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HTDS - Hard To Treat Diseases

HTDS 0.0000200

0.0%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: ThinkingBig	12/7/2005 11:42:03 AM
	of 271

Hard to Treat Diseases, Incorporated Announces: Appellees' Cross-Appeal Dismissed by U.S. Court of Appeals Wednesday December 7, 10:59 am ET DELRAY BEACH, FL--(MARKET WIRE)--Dec 7, 2005 -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces that on December 2, 2005 the U.S. Court of Appeals dismissed the cross-appeal by Shinn Capital Group, Inc., Shinn and Knight for lack of jurisdiction. The complete text of the dismissal will be posted on HTTD's website as soon as it's available. HTTD's briefs relating to the appeal are due by December 28, 2005. The briefs will be filed with the U.S. Court of Appeals prior to the due date and will be posted on the Company's website at: www.htdsotc.com. According to HTTD, "Shinn's attempts have been futile in accessing any of HTTD's confidential information regarding the Company's research plans, testing results or provisional patent information. The appropriate motions have been filed by HTTD's attorneys with the courts in Oklahoma and Colorado in order to enlighten the courts of Shinn's intentions of stealing HTTD's assets and attempting to circumvent the authority of the courts in other jurisdictions. Shareholders will be kept informed." Mediation is still an option regarding the potential settlement of the appeal and securing the rights to Tubercin. The Company's position grows stronger each day in relation to benefiting patients and increasing shareholder value. HTTD's CEO Colm King states, "HTTD's provisional patent will be enhanced this month. Additional patent information and updates on the Company's negotiations with a major drug firm will be available within the next 30 days."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next